-$1.51
$7.46
bear -$1.51
base $1.05
bull $7.46
margin of safety $0.40
market price* $1.12
Business condition attached to the margin of safety
Two consecutive fiscal quarters of operating profit (or an operating loss under $100,000) on quarterly revenue of at least $6 million, with no new share offering in between.
Sonoma Pharmaceuticals makes stabilized hypochlorous acid (HOCl) solutions, sold under names such as Microcyn, Reliefacyn, Regenacyn, Levicyn and Epicyn, for wound care, dermatology, eye care, podiatry and animal health. Everything is manufactured at one plant in Zapopan, Mexico, and products are sold directly or through partners in more than 55 countries. In the year to March 31, 2026, revenue rose 37% to $19.5 million: United States $5.7 million (up 117% on new over-the-counter retail products), Europe $6.9 million, Asia $2.9 million, Latin America $2.4 million (down 20%), and the rest of the world $1.7 million. The central fact is that the business has never made money. Measured as the cash an owner could take out after keeping the business running and after the cost of stock-based pay, it lost money in every one of the last ten years: $4.8 million in fiscal 2024, $3.0 million in 2025 and $3.4 million in 2026. The accumulated deficit is $201 million. Losses have been paid for by selling new shares nearly every year. After reverse splits of 1-for-9 (2019) and 1-for-20 (2024), there are now about 4.79 million shares, up from about 1.8 million in March 2026, mainly because of a 2.96 million share offering in April 2026. We start from the median of the last three years, a loss of about $3.4 million a year (about $0.71 per current share). Earlier years belong to a different business, before the Latin American rights were sold to Invekra, U.S. prescription products moved to distributors in fiscal 2022, and pandemic disinfectant sales faded. What has changed is operating leverage. Gross margin held at 38% in both of the last two years. Selling and administrative costs rose only 3% (to $7.6 million) while revenue grew 37%, so the operating loss shrank from $3.7 million to $2.5 million. The larger loss on our measure in fiscal 2026 came from currency: other income of $0.8 million the year before, mostly currency gains, became other expense of $1.0 million, mostly currency losses. In the quarter to June 30, 2026, revenue rose 60% to $6.4 million, gross margin was about 40%, and the operating loss was only $40,000. The named drivers are new U.S. retail and distribution launches: a burn-relief hydrogel in CVS and Walmart (March 2026), Aquanil AD for Person & Covey (March 2026), a wound cleanser for Medline (October 2025) and diaper-rash products at Walmart (August 2025). Acne products also launched in about 1,200 U.K. stores in April 2025. Base case ($1.05 per share): revenue of about $23.5 million in the first year. That is more than the last fiscal year but deliberately below four times the latest quarter, because a single strong quarter may include stocking orders for new retail launches. Growth then slows from 15% to 3% a year, reaching about $44 million in year ten. Gross margin stays at 39%. Operating costs of about $10.6 million grow 4% a year. Results break even in year four, and owner earnings peak near $1.5 million in year eight. We assume about 10% more shares are sold to fund the growth, because customer receivables and inventory must grow with sales. After year ten, earnings fade to zero over the following decade. The company holds its regulatory clearances and more than 20 years of HOCl manufacturing experience, but it has never shown a lasting profit that would justify more. Bull case ($7.46 per share): the latest quarter's pace of about $25.6 million a year holds. Growth runs from 20% down to 3%, gross margin improves to 40% on higher factory volume, and costs grow 4.5% a year. Owner earnings turn positive in year two and reach about $5 million on roughly $56 million of revenue by year ten, then fade over fifteen years. No new shares are needed in this case. Bear case (minus $1.51 per share): revenue stalls near $22 million. Two evidenced risks drive this. First, the Latin American sales are overflow manufacturing for Invekra, which moved most of that production in-house in 2020. Second, one customer that was 21% of revenue in fiscal 2025 fell below 10% in fiscal 2026. In this case losses start near $2.4 million a year, and cost cuts bring them to break-even only by year seven, with nothing after that. The business would consume about $7 million more than it generates, measured in today's money. That is more than the $5.3 million of cash held at June 30, 2026, so further share sales would be needed. In this case the business is worth less than nothing to its owners. The negative figure reflects ongoing operating losses, not borrowing; debt is minimal. Accounting judgements: stock-based pay is treated as a real cost. About $0.4 million a year of Mexican withholding tax is accrued on money owed to the U.S. parent by the Mexican subsidiary, and we treat it as a cost. The balance now stands at $5.6 million and would be paid only if that money is sent back to the U.S. The filing also notes that about $16.5 million of Mexican tax would fall due if that intercompany debt were forgiven or converted into equity. This makes it costly to move profits out of Mexico. Cash on hand is not added to the value. The margin-of-safety price applies only if the recent improvement proves lasting. The value here depends on whether operating losses shrink toward zero without more rounds of heavy share sales. Two more quarters of near break-even results would support the base case. A return to quarterly losses near $1 million would point toward the bear case.